Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Total Current Liabilities (2020 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Total Current Liabilities for 6 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • Quarterly Total Current Liabilities fell 46.8% to $8.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $8.4 million through Dec 2025, down 46.8% year-over-year, with the annual reading at $8.4 million for FY2025, 46.8% down from the prior year.
  • Total Current Liabilities hit $8.4 million in Q4 2025 for Bolt Biotherapeutics, down from $10.0 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $24.2 million in Q3 2022 to a low of $8.4 million in Q4 2025.
  • Historically, Total Current Liabilities has averaged $17.4 million across 5 years, with a median of $18.0 million in 2024.
  • Biggest five-year swings in Total Current Liabilities: soared 89.35% in 2021 and later tumbled 46.8% in 2025.
  • Year by year, Total Current Liabilities stood at $21.3 million in 2021, then grew by 8.39% to $23.1 million in 2022, then fell by 11.51% to $20.5 million in 2023, then decreased by 22.49% to $15.9 million in 2024, then crashed by 46.8% to $8.4 million in 2025.
  • Business Quant data shows Total Current Liabilities for BOLT at $8.4 million in Q4 2025, $10.0 million in Q3 2025, and $12.3 million in Q2 2025.